CURX Curanex Pharmaceuticals Inc
Legal ·
Curanex Pharmaceuticals is a defendant, with underwriters Dominari Securities LLC, Pacific Century Securities, LLC and Revere Securities LLC, in two New York class actions over its August 2025 IPO. Both suits allege Securities Act violations in the offering documents.
Curanex's 1-for-20 reverse split took effect on August 20, 2026. Nasdaq closed its bid-price matter on September 3, after the stock traded at or above $1.00 for ten consecutive business days.
Curanex says its cash will not last twelve months, a reversal of the no-doubt finding in its first-quarter report. Prepaid research payments have so far held cash use well below its losses.
Curanex paid $408,537.32 on two notes held by its secretary, Dian Ying Jing, the wife of its chief executive. The payments came on September 23 and 24, 2025, well before the notes matured in 2027.
Dominari Securities bought 562,500 more shares at the $4.00 IPO price. Total gross proceeds from the offering reached $17,250,000.
Curanex closed its initial public offering of 3,750,000 shares at $4.00 a share on August 27, 2025. Dominari Securities led the underwriters, and the proceeds are earmarked for Phyto-N, a lead drug candidate for ulcerative colitis.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $3.0 million | |
| Net income (loss) | -$4.2 million | -$361,506 |
| Cash from operations | -$10.5 million | -$555,575 |
| Cash and equivalents | $5.0 million |
Our latest story on this, dated Aug 20, 2026: "Curanex regains Nasdaq bid-price compliance after 1-for-20 reverse split". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Oct 19, 2026: "Curanex discloses two New York class actions tied to its August 2025 IPO". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 14, 2026: "Curanex flags going-concern doubt with $2.94 million in cash at June 30". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Oct 19, 2026: "Curanex discloses two New York class actions tied to its August 2025 IPO". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Oct 19, 2026: "Curanex discloses two New York class actions tied to its August 2025 IPO". The story links the filing or release it is based on. Read the story.
Curanex Pharmaceuticals Inc trades under the ticker CURX on NASDAQ.
Curanex Pharmaceuticals Inc is listed on NASDAQ.
The SEC Central Index Key (CIK) for Curanex Pharmaceuticals Inc is 2025942. Its filings are on SEC EDGAR.
31,364,812 shares as of 2026-08-14, per the cover page of its 10-Q filed 2026-08-14.
Our directory records Curanex Pharmaceuticals Inc under United States.
Our directory classifies Curanex Pharmaceuticals Inc as: Biopharma / pharmaceutical profile checked. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Curanex Pharmaceuticals Inc is US23126K3041.
aibio.space lists Curanex Pharmaceuticals Inc among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as NV.
Curanex Pharmaceuticals Inc reported a net loss of $4.2 million for the fiscal year ended Dec 31, 2025, and used $10.5 million of cash in operations, per its annual report to the SEC.
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 8-K (Items 8.01). Source
The company says Robert Lovett filed another putative securities class action. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
A one-for-twenty reverse split took effect to address minimum bid-price compliance. Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,9.01). Source
The interim report disclosed unresolved substantial doubt and inadequate twelve-month cash resources. Source
The company says Daymond Morales and others filed a putative securities class action. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Nasdaq granted an additional 180-day period, until 2026-11-02, to regain bid-price compliance; the company later reported that it had regained compliance. Source
Management concluded earlier substantial doubt was alleviated in its annual report. Source
Continued-service employment agreements for the chief executive and chief operating officer took effect. Source
Wanjun Zhang became chief financial officer and treasurer under a consulting agreement. Source
Haiyan Yang resigned as chief financial officer and treasurer, without a reported disagreement. Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Nasdaq notified the company of minimum bid-price noncompliance; the matter was subsequently closed. Source
An 8-K reports 28,312 shares issued to settle an earlier subscription; the annual report gives a different issuance date. Source
Curanex prepaid the second related-party note. Source
Curanex prepaid the first of its two related-party notes. Source
The full underwriter over-allotment purchase closed, adding $2.25 million gross. Source
Reported a financing. SEC Form 8-K (Items 8.01,9.01). Source
Curanex closed its initial public offering for $15 million gross. Source
Reported a financing. SEC Form 8-K (Items 1.01,8.01,9.01). Source
Curanex signed the underwriting agreement for its initial public offering. Source
The company received a further $200,000 loan from its secretary. Source
The company received a $200,000 related-party loan from its secretary. Source
The annual report describes approval of a three-for-five reverse split effective on this date. Source
Curanex reported that the matter was closed after Nasdaq confirmed compliance on 2026-09-03. This does not guarantee future compliance. Source
It reported $2,938,463 in cash and cash equivalents at 2026-06-30. This is a historical balance, not a current daily cash figure. Source
Management said cash would not cover at least twelve months from issuance of the interim statements. It did not give an exact exhaustion date. Source
Yes. Management disclosed substantial doubt and said its plans did not alleviate it. Source
It implemented a one-for-twenty reverse split effective on 2026-08-20. Source
The initial closing raised $15 million gross. Later option-exercise proceeds were additional. Source
The company disclosed two preliminary putative securities class actions. Source
The issuer says neither complaint asserts a fraud claim against the company. This describes the issuer disclosure rather than an independent complaint review. Source
The latest annual audit report is signed by Kreit & Chiu CPA LLP. Source
No. It registers remaining shares issuable under an incentive plan and does not announce a cash offering. Source
The latest opened ownership table reports overlapping beneficial interests for Jun Liu and Dian Ying Jing and a separate interest for Chang Liu. Source
No. The quarterly cover reports a dated pre-split count; the later corporate-action report estimates the adjusted amount. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio